Here are the latest stories being discussed in biopharma today:

FDA flags ‘early deaths’ in Abecma and Carvykti multiple myeloma trials

An FDA advisory committee is set to vote on the benefit-risk ratio of two CAR-T therapies, Abecma and Carvykti, for multiple myeloma treatment. The review comes as regulators note an increase in early deaths among trial participants, causing concern about their use.

Eli Lilly CEO Discusses Future of Pharma

Eli Lilly CEO David Ricks expressed his views on Alzheimer’s, AI, China, direct-to-consumer drug sales, and the future ‘golden era’ of pharmaceuticals following the company’s success with its obesity drugs. Ricks also emphasized the need for expansion in supply for Lilly’s obesity and diabetes treatments, Mountjaro and Zepbound.

Alnylam’s New Campaign on Health History and Heredity

Alnylam Pharmaceuticals has launched their latest digital campaign addressing hereditary ATTR (hATTR) amyloidosis. The campaign seeks to educate families on the importance of genetic testing to understand the risks of inheriting the condition, which affects an estimated 50,000 people worldwide.

Court Sides with Arkansas in PhRMA Lawsuit over 340B Expansion

A federal appeals court ruled in favor of Arkansas against a lawsuit brought by the pharmaceutical lobbying group PhRMA. The lawsuit challenged a 2021 state law that prohibited manufacturers from limiting the availability of discounted drugs at certain pharmacies, with the court deciding in Arkansas’ favor.

Stable Pharma Industry Reputation After Covid, According to Harris Poll

According to the latest Harris Poll data, the pharmaceutical industry has managed to maintain the reputation gains it made during the Covid-19 pandemic. Positive perception of the industry remains steady at 45%, consistent with last year’s findings.

Novartis Acquires More of IFM Therapeutics

Novartis has acquired more of IFM Therapeutics, focusing on the company’s STING antagonists. Novartis already paid for an option and collaboration agreement a few years ago and now has full rights to IFM Due’s portfolio of STING antagonists. The drugs could become treatments for diseases driven by inflammation.